Valneva SE (VALN) EBITDA (2021 - 2026)
Valneva SE's (VALN) quarterly EBITDA came in at -$21.3 million in Q1 2026, down 3276.1% year-on-year from $670873.2 in Q1 2025, and up 15.65% quarter-over-quarter from -$25.3 million in Q4 2025.
Valneva SE (VALN) EBITDA (2021 - 2026) Analysis & Trends
Valneva SE has disclosed EBITDA across 6 years of filings, most recently posting -$21.3 million for Q1 2026.
- EBITDA for Q1 2026 came in at -$21.3 million, down 3276.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$89.7 million (down 104.67% YoY), and the FY2025 annual result was -$69.1 million, down 296.67% from the prior year.
- EBITDA came in at -$21.3 million for Q1 2026 at Valneva SE, up from -$25.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $38.7 billion in Q4 2022 to a low of -$38.1 billion in Q3 2022.
- The 5-year median for EBITDA is -$18.1 million (2024), against an average of $14.7 million.
- Peak annual rise in EBITDA reached 19080.79% in 2022, while the deepest fall reached 21259.55% in 2022.
- Valneva SE's EBITDA stood at $38.7 billion in 2022, then slumped by 100.05% to -$20.7 million in 2023, then climbed by 18.79% to -$16.8 million in 2024, then slumped by 50.56% to -$25.3 million in 2025, then climbed by 15.65% to -$21.3 million in 2026.
- The last three EBITDA figures came in at -$21.3 million (Q1 2026), -$25.3 million (Q4 2025), and -$37.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -65.83 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -21.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.31 Mn |
| Dec 31, 2025 | -25.26 Mn |
| Sep 30, 2025 | -37.06 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -631,130.66 |
| Dec 31, 2024 | -16.78 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -18.09 Mn |
| Mar 31, 2024 | 79.30 Mn |
| Dec 31, 2023 | -20.66 Mn |
| Sep 30, 2023 | -19.27 Mn |
| Jun 30, 2023 | -17.42 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Dec 31, 2022 | 38.67 Bn |
| Sep 30, 2022 | -38.14 Bn |
| Jun 30, 2022 | -125.49 Mn |
| Mar 31, 2022 | -20.65 Mn |
| Dec 31, 2021 | 201.58 Mn |
| Sep 30, 2021 | -178.58 Mn |
| Jun 30, 2021 | -62.38 Mn |